Pluri vs SAB Biotherapeutics
PLUR and SABS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLUR and SABS compare
SAB Biotherapeutics is the larger company, worth 21 times as much as Pluri ($269M against $13.0M).
SAB Biotherapeutics scores higher on the StockData Score (8 against 4 for Pluri), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLUR | SABS |
|---|---|---|
| Size and price | ||
| Market cap | $13.0M | $269M |
| Share price | $1.05 | $2.96 |
| Change, 1 year | −76.4% | −13.2% |
| Change, 5 years | −95.0% | −97.3% |
| Beta (5Y) | 0.95 | 1.38 |
| Employees | 92 | 86 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.9× | – |
| P/B | – | 1.3× |
| FCF yield | −148% | – |
| Growth | ||
| Revenue growth (TTM) | 10.0% | – |
| Net income growth (TTM) | – | −530% |
| Profitability | ||
| Gross margin | 52.0% | – |
| Operating margin | −2341% | – |
| Net margin | −1944% | – |
| FCF margin | −1318% | – |
| Return on equity | – | −42.8% |
| Return on invested capital | – | −83.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −36.8× | – |
| Current ratio | 0.27 | 7.28 (better) |
| Altman Z-score | −32.23 | 4.78 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.22% | 75.2% |
| Held by insiders | 54.6% | 30.2% |
| Insider net buying, 12 months | $1.3M | – |
| Short interest, % of float | 1.4% | 7.9% |
Go deeper
- PLUR stock overview
- PLUR income statement
- PLUR valuation and score
- SABS stock overview
- SABS income statement
- SABS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.